News

Zai Lab's ZL-1310 Shows Encouraging Outcomes in Lung Cancer

Zai Lab's ZL-1310 Shows Encouraging Outcomes in Lung Cancer

Introduction to ZL-1310 and Its Potential

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has been making waves in the biopharmaceutical sphere, particularly with its investigational drug, ZL-1310. This new antibody-drug conjugate (ADC) is specifically aimed at combating extensive-stage small cell lung cancer (ES-SCLC), a challenging and aggressive form of cancer. Recent data from an extensive Phase 1a/1b study presents a promising view of ZL-1310's efficacy and safety profile in treating patients who have exhausted conventional chemotherapy options.

Study Overview and Key Findings

Investigation and Results

The recent presentation at the EORTC-NCI-AACR Symposium highlighted the ongoing global study of ZL-1310. This investigation involved 25 patients across various dosage cohorts, including 0.8 mg/kg to 2.4 mg/kg. Nineteen patients were able to provide evaluable tumor assessments, leading to notable results.

Objective Response Rates (ORR)

From the 19 assessed, the ORR stood at an impressive 74%, with anti-tumor activity observed across all dosing levels. This is particularly significant as responses were recorded in patients with varying DLL3 H-scores, underscoring the drug's potential effectiveness in a diverse patient population. The data indicates that tumor expressions play a critical role in the response, as no effect was noted in patients lacking DLL3 expression.

Safety Profile of ZL-1310

Adverse Events Recorded

Alongside efficacy, safety remains a primary concern in cancer treatments. ZL-1310 exhibited a manageable safety profile, with treatment-emergent adverse events primarily classified as Grade 1 or 2. Instances of more severe reactions, classified as Grade 3 or above, occurred in only 20% of the patients. This result suggests a relatively favorable toxicity profile, a vital aspect when evaluating treatment options for patients with little remaining recourse against their disease.

The Implications for Patients

Breaking New Ground in Treatment

As the data indicates, the group of patients treated with ZL-1310 showed encouraging results, especially those with previously treated brain metastases, all of whom achieved a partial response. The presence of DLL3 expression and its correlation with the efficacy of ZL-1310 paves the way for potential biomarker-driven therapies in the future, an essential step forward in precision medicine.

Expert Commentary on ZL-1310

Dr. Alex Spira, associated with Virginia Cancer Specialists, shared insights on the study's findings, expressing optimism about ZL-1310's ability to deliver meaningful responses in an otherwise difficult treatment landscape. His comments emphasize the urgent need for innovative therapies in ES-SCLC and validate the continued assessment of ZL-1310 as both a standalone treatment and in conjunction with other therapies, such as immune checkpoint inhibitors.

The Vision of Zai Lab

Zai Lab continues to highlight their commitment to innovative cancer therapies. Rafael G. Amado, M.D., articulated the company's endorsement of ZL-1310's potential based on the positive preliminary findings, reflecting Zai Lab's dedication to advancing groundbreaking oncology programs. This dedication is vital to addressing significant unmet medical needs globally.

Webcast Access and Company Background

For those interested in further discussions about ZL-1310 and its implications, a webcast is scheduled for October 24, 2024, at 8:30 a.m. ET. Registration is required for those wanting to participate in the conference call, showcasing Zai Lab’s proactive approach to keeping the community informed.

About Zai Lab

Based in China and the United States, Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is dedicated to tackling significant medical challenges through innovative drug development in oncology, immunology, and other critical areas. Their goal remains firmly rooted in positively impacting patient care both locally and globally.

Insight into ZL-1310

ZL-1310 is not just another therapy; it represents hope for many battling advanced neuroendocrine tumors. By using a humanized anti-DLL3 monoclonal antibody combined with a unique payload, Zai Lab positions ZL-1310 at the forefront of novel cancer treatments, designed to overcome the challenges presented by previous generations of ADCs.

Frequently Asked Questions

What is ZL-1310?

ZL-1310 is an investigational ADC targeting DLL3 for patients with extensive-stage small cell lung cancer.

What are the efficacy results for ZL-1310?

The drug demonstrated a 74% objective response rate in a recent study.

How does ZL-1310’s safety profile look?

It has been well tolerated, with the majority of adverse events being low in severity.

Who is leading the clinical trials for ZL-1310?

The trials are led by Zai Lab, a biopharmaceutical company focused on innovative cancer treatments.

What is the future of ZL-1310?

The drug is expected to advance into further clinical evaluation, exploring its use as both a monotherapy and in combination with other treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 140

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 95

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 126

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 116

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin Faces Criticism While BlackRock Sees Financial Success

Updated Category News Views 167

Bitcoin Under Scrutiny In recent discussions, Peter Schiff has taken to social media to share his critical views on Bitcoin, branding it as a "fake asset." His assertion comes after Bitcoin's price retracement from its historic highs, indicating a significant downturn. Currently, Bitcoin is trading at around $81,000 after once peaking at $110,000. Schiff argues that the...

Continue Reading
Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Updated Category News Views 213

Valneva Expands IXIARO Vaccine Supply with New Contract Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's...

Continue Reading
EFGH and Minerva Forge Strategic Partnership for Data Centres

Updated Category News Views 118

EFGH and Minerva Unite to Enhance Ghana's Digital Landscape In a landmark agreement, Embed Financial Group Holdings (EFGH) has joined forces with Minerva Data Limited, a prominent player in digital infrastructure, to create advanced data centres and strengthen the technology ecosystem in Ghana. This collaboration marks a significant step in addressing the growing demand...

Continue Reading
Landsea Homes Achieves Remarkable Growth in Q3 Results

Updated Category News Views 50

Strong Financial Performance in Q3 Landsea Homes Corporation (NASDAQ: LSEA) reported impressive financial results for the third quarter, demonstrating robust performance in the residential homebuilding sector. For the quarter, Landsea Homes achieved a net income of $11.1 million, translating to $0.30 per share. This marks a 29% increase in net income compared to the...

Continue Reading
Urban Logistics REIT: Key Disclosure Insights for Investors

Updated Category News Views 219

Understanding the Disclosure from Urban Logistics REIT In the realm of public trading, disclosures play a pivotal role in keeping investors informed about changes in significant stakes within companies. Recently, Urban Logistics REIT Plc, underlining its commitment to transparency, provided valuable insights through its disclosure concerning investor positions, managed by...

Continue Reading